Fig. 4

Inhibition of CD38 expression improves energy metabolism disorder in APP/PS1 mice and reduces the neuroinflammatory response. Scale bar: 50 μm. A ATP level of the hippocampus. B ATP level of the cortex. C NAD + level of the hippocampus. D NADH level of the hippocampus. E NAD + /NADH ratio of the hippocampus. F NAD + level of the cortex. G NADH level of the cortex. H NAD + /NADH ratio of the cortex. I MMP of the hippocampus. J MMP of the cortex. K ROS level of the hippocampus. L ROS level of the cortex. M IL-1β level of the serum. N TNF-α level of the serum. O IL-6 level of the serum. P IL-1β level of the hippocampus. Q TNF-α level of the hippocampus. R IL-6 level of the hippocampus. S IL-6 level of the cortex. T TNF-α level of the cortex. U Representative images of Iba1 + and senile plaque immunolabeling in the hippocampus and cortex. *P < 0.05 and **P < 0.01 vs. control group; ^#P < 0.05 and ^##P < 0.01 vs. model group; ^△P < 0.05 and ^△△P < 0.01